Literature DB >> 22023024

The pharmacogenetics of the response to warfarin in Chinese.

May P S Lam1, Bernard M Y Cheung.   

Abstract

Warfarin is a commonly used oral anticoagulant with a narrow therapeutic range and large interindividual variability in daily dose. Compared with Caucasians, Chinese are known to require lower doses of warfarin. Differences between Caucasians and Chinese in the allelic frequencies of two genes, CYP2C9 and VKORC1, largely explain the difference in dose requirement. There are other genetic polymorphisms that may further explain the response to warfarin. The VKORC1 genotype is an important determinant of response to warfarin in Chinese, but some genetic variants found in other ethnic groups that have a large effect on warfarin response and dosing are not commonly found in Chinese. Therefore, it is important to recognize and beware of ethnic differences in the pharmacogenetics of the response to warfarin, especially in the design of algorithms to aid dosing in clinical practice.
© 2011 The Authors. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22023024      PMCID: PMC3370339          DOI: 10.1111/j.1365-2125.2011.04097.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  50 in total

Review 1.  The vitamin K-dependent carboxylase.

Authors:  Steven R Presnell; Darrel W Stafford
Journal:  Thromb Haemost       Date:  2002-06       Impact factor: 5.249

2.  Translational aspects of genetic factors in the prediction of drug response variability: a case study of warfarin pharmacogenomics in a multi-ethnic cohort from Asia.

Authors:  S L Chan; C Suo; S C Lee; B C Goh; K S Chia; Y Y Teo
Journal:  Pharmacogenomics J       Date:  2011-03-08       Impact factor: 3.550

3.  Warfarin dose related to apolipoprotein E (APOE) genotype.

Authors:  Hugo Kohnke; Kristina Sörlin; Göran Granath; Mia Wadelius
Journal:  Eur J Clin Pharmacol       Date:  2005-06-11       Impact factor: 2.953

4.  Common VKORC1 and GGCX polymorphisms associated with warfarin dose.

Authors:  M Wadelius; L Y Chen; K Downes; J Ghori; S Hunt; N Eriksson; O Wallerman; H Melhus; C Wadelius; D Bentley; P Deloukas
Journal:  Pharmacogenomics J       Date:  2005       Impact factor: 3.550

5.  A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity.

Authors:  Hsiang-Yu Yuan; Jin-Jer Chen; M T Michael Lee; Ju-Chieh Wung; Ying-Fu Chen; Min-Ji Charng; Ming-Jen Lu; Chi-Ren Hung; Chun-Yu Wei; Chien-Hsiun Chen; Jer-Yuarn Wu; Yuan-Tsong Chen
Journal:  Hum Mol Genet       Date:  2005-05-11       Impact factor: 6.150

6.  Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9.

Authors:  Ronen Loebstein; Manuela Vecsler; Daniel Kurnik; Naomi Austerweil; Eva Gak; Hillel Halkin; Shlomo Almog
Journal:  Clin Pharmacol Ther       Date:  2005-05       Impact factor: 6.875

7.  Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation?

Authors:  J H S You; F W H Chan; R S M Wong; G Cheng
Journal:  Br J Clin Pharmacol       Date:  2005-05       Impact factor: 4.335

8.  Gamma-glutamyl carboxylase (GGCX) microsatellite and warfarin dosing.

Authors:  Leslie Y Chen; Niclas Eriksson; Rhian Gwilliam; David Bentley; Panos Deloukas; Mia Wadelius
Journal:  Blood       Date:  2005-11-15       Impact factor: 22.113

9.  Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.

Authors:  Christina L Aquilante; Taimour Y Langaee; Larry M Lopez; Hossein N Yarandi; Jennifer S Tromberg; Dagmara Mohuczy; Katherine L Gaston; Cassandra D Waddell; Mark J Chirico; Julie A Johnson
Journal:  Clin Pharmacol Ther       Date:  2006-02-28       Impact factor: 6.875

10.  A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.

Authors:  Giovanna D'Andrea; Rosa Lucia D'Ambrosio; Pasquale Di Perna; Massimiliano Chetta; Rosa Santacroce; Vincenzo Brancaccio; Elvira Grandone; Maurizio Margaglione
Journal:  Blood       Date:  2004-09-09       Impact factor: 22.113

View more
  16 in total

1.  Warfarin-induced life-threatening bleeding associated with a CYP3A4 loss-of-function mutation in an acute limb ischemia patient: Case report and review of the literature.

Authors:  Xiao-Wei Ma; Chang-Ning Hao; Zhi-Chun Gu; Meng Ye; Min Li; Lan Zhang
Journal:  Exp Ther Med       Date:  2017-06-14       Impact factor: 2.447

Review 2.  Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin.

Authors:  Erik Fung; Nikolaos A Patsopoulos; Steven M Belknap; Daniel J O'Rourke; John F Robb; Jeffrey L Anderson; Nicholas W Shworak; Jason H Moore
Journal:  Semin Thromb Hemost       Date:  2012-10-06       Impact factor: 4.180

3.  Variability in Human In Vitro Enzyme Kinetics.

Authors:  Christopher R Gibson; Ying-Hong Wang; Ninad Varkhede; Bennett Ma
Journal:  Methods Mol Biol       Date:  2021

4.  Does ethnicity play a role in the dosing of warfarin in Hawai'i?

Authors:  Sydney Y Tatsuno; Eric M Tatsuno
Journal:  Hawaii J Med Public Health       Date:  2014-03

5.  Clinical application of a new warfarin-dosing regimen based on the CYP2C9 and VKORC1 genotypes in atrial fibrillation patients.

Authors:  Nian-Xin Jiang; Jun-Wei Ge; Yu-Qiong Xian; Shao-Ying Huang; Yan-Song Li
Journal:  Biomed Rep       Date:  2016-02-26

6.  Warfarin dosage response related pharmacogenetics in Chinese population.

Authors:  Siyue Li; Yuangao Zou; Xia Wang; Xunbei Huang; Yong Sun; Yuqing Wang; Li Dong; Hong Jiang
Journal:  PLoS One       Date:  2015-01-16       Impact factor: 3.240

7.  Identification of CYP2C9 and VKORC1 polymorphisms in Iranian patients who are under warfarin therapy.

Authors:  Behzad Poopak; Saghar Rabieipoor; Nazila Safari; Emadedin Naraghi; Fatemeh Sheikhsofla; Gelareh Khosravipoor
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2015-10-01

8.  The allele frequency of CYP2C9 and VKORC1 in the Southern Khorasan population.

Authors:  Fariba Emadian Razavi; Asghar Zarban; Fatemeh Hajipoor; Mohsen Naseri
Journal:  Res Pharm Sci       Date:  2017-06

9.  Long-term anticoagulation in the extreme elderly with the newer antithrombotics: safe or sorry?

Authors:  Jun R Chiong; Rebecca J Cheung
Journal:  Korean Circ J       Date:  2013-05       Impact factor: 3.243

10.  Do NOACs Improve Antithrombotic Therapy in Secondary Stroke Prevention in Nonvalvular Atrial Fibrillation?

Authors:  Yi-Pin Lin; Teng-Yeow Tan
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.